Skip to main content

Table 1 Characteristics of eligible studies included in the meta-analysis

From: Prognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: a meta-analysis

Study

Patient source

Study duration

Follow-up duration (range), months

Method

Antibody source for IHC

Dilution of antibody

Defination of positivity

Histology type

Mean age (range), years

Number of patients

HIF + (%)

Study design

NOS score

Zhao et al. (2015)

China

2002–2012

NR (3–107)

IHC

Novus

1:100

>25 %

OS

NR

88

56.8

Re

M

7

Kim et al. (2015)

Korea

1998–2007

38 (2–187)

IHC

Abcam

1:1000

>50 %

STS

57 (1–82)

55

54.5

Re

S

8

Hu et al. (2015)

China

2006–2011

36

IHC

Proteintech

1:200

SS

OS

NR

50

58.0

Pro

M

9

Guo et al. (2014)

China

2003–2007

NR

IHC

Abcam

1:200

>10 %

OS

NR

98

79.9

Re

S

7

Smeland et al. (2012)

Norway and Russia

1973–2006

37.6 (0.1–391.7)

IHC

Novus

1: 3500

SS

STS

60 (0–91)

200

61.5

Re

M

8

Chen et al. (2011)

China

NR

34 (4–98)

IHC

Abcam

1:50

>10 %

CS

47.9 (18–72)

34

58.8

Re

S

8

Chen et al. 2012a, b

China

2000–2009

29 (6–100)

IHC

Santa

1:100

SS

OS

18.5 (11–72)

49

55.1

Pro

S

9

Zeng et al. (2010)

China

NR

NR

IHC

NR

1:100

SS

OS

18.6 (7–49)

45

55.6

Re

S

7

Huang et al. (2010)

USA

1987–2006

27.5 (0.7–229)

IHC

Labvision

NR

>10 %

STS

64 (21–85)

39

41.0

Re

S

7

Boeuf et al. (2010)

Germany

NR

116.3

IHC

BD

1:1250

SS

CS

NR

65

33.8

Re

M

8

Hoffmann et al. (2009)

Germany

NR

NR

RT-RCP

NR

STS

57 (16–85)

45

64.4

Re

S

7

Mizobuchi et al. (2008)

USA

NR

NR

IHC

Novus

1:100

SS

OS

21 (7–38)

48

37.5

Re

S

7

Kubo et al. (2008)

Japan

1986–2001

78 (1–192)

IHC

Novus

1:1000

>10 %

CS

42 (15–71)

20

40.0

Re

S

8

Chen et al. (2008)

China

NR

NR

IHC

NeoMarkers

1:70

SS

OS

NR (3–63)

25

68.0

Re

S

6

Yang et al. (2007)

China

NR

50 (13–86)

IHC

Santa

1:50

SS

OS

19 (5–56)

39

43.6

Re

S

8

Shintani et al. (2006)

Japan

NR

39 (5–181)

IHC

Novus

1:1000

SS

STS

63 (12–85)

42

52.4

Re

S

7

  1. NR not reported, IHC immunohistochemistry, RT-PCR reverse transcription-polymerase chain reaction, SS score system combining intensity and percentage, OS osteosarcoma, STS soft tissue sarcoma, CS chondrosarcoma, Re retrospective, Pro prospective, M multi-center, S single center, NOS Newcastle–Ottawa Scale